Nanotech Investing Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
Nanotech Investing Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT XR
Nanotech Investing Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET
Nanotech Investing Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
